Melphalan flufenamide is a peptide-conjugated alkylating agent designed to be taken up by cells and cleaved by intracellular peptidases to release melphalan. Melphalan alkylates DNA, causing DNA crosslinking and inhibition of DNA synthesis and tumour-cell proliferation.
Indications / reported uses
Historical US indication: in combination with dexamethasone for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy and refractory to specified prior agents. US approval was withdrawn effective 23 February 2024; do not present it as a current US-authorised treatment.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Melphalan Flufenamide Environmental Risk Assessment (ERA) (the Melphalan Flufenamide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.